Slideshows Images Quizzes


Last reviewed on RxList: 12/15/2016
ConZip Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 02/03/2017

ConZip (tramadol hydrochloride) is an analgesic (pain reliever) used to treat moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. Common side effects of ConZip include:

ConZip is an extended-release formulation intended for once a day dosing, starting at an initial dose of 100 mg once daily and adjusted as necessary by 100 mg increments every five days to achieve a balance between relief of pain and tolerability. ConZip may interact with antidepressants, MAOIs, neuroleptics, quinidine, ketoconazole, antibiotics, lithium, St. John's Wort, triptans, opioids, anesthetic agents, narcotics, phenothiazines, tranquilizers, sedative hypnotics, digoxin, warfarin, carbamazepine, or rifampin. Tell your doctor all medications and supplements you use. During pregnancy, ConZip should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our ConZip (tramadol hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

ConZip Professional Information


The following serious or otherwise important adverse reactions are described in greater detail, in other sections:

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

ConZip™ capsules were administered to a total of 1987 patients in clinical trials. These included four double-blind and one long-term, open-label study in patients with osteoarthritis of the hip and knee. A total of 812 patients were 65 years or older. Adverse reactions with doses from 100 mg to 300 mg in the four pooled, randomized, doubleblind, placebo-controlled studies in patients with chronic non-malignant pain are presented in the following table (see Table 1).

Table 1: Incidence (%) of patients with adverse reaction rates ≥ 5% from four doubleblind, placebo controlled studies in patients with moderate to moderately severe chronic pain by dose (N=1917).

Preferred Term CONZIP™ PLACEBO
n (%)
100 mg
n (%)
200 mg
n (%)
300 mg
n (%)
Headache 99 (23.1) 96 (22.1) 200 (19.0) 128 (19.8)
Nausea 69 (16.1) 93 (21.4) 265 (25.1) 37 (5.7)
Somnolence 50 (11.7) 60 (13.8) 170 (16.1) 26 (4.0)
Dizziness 41 (9.6) 54 (12.4) 143 (13.6) 31 (4.8)
Constipation 40 (9.3) 59 (13.6) 225 (21.3) 27 (4.2)
Vomiting 28 (6.5) 45 (10.4) 98 (9.3) 12 (1.9)
Arthralgia 23 (5.4) 20 (4.6) 53 (5.0) 33 (5.1)
Dry Mouth 20 (4.7) 36 (8.3) 138 (13.1) 22 (3.4)
Sweating 18 (4.2) 23 (5.3) 71 (6.7) 4 (0.6)
Asthenia 15 (3.5) 26 (6.0) 91 (8.6) 17 (2.6)
Pruritus 13 (3.0) 25 (5.8) 77 (7.3) 12 (1.9)
Anorexia 9 (2.1) 23 (5.3) 60 (5.7) 1 (0.2)
Insomnia 9 (2.1) 9 (2.1) 53 (5.0) 11 (1.7)

The following adverse reactions were reported from all chronic pain studies (N=1917). The lists below include adverse reactions not otherwise noted in Table 1.

Adverse reactions with incidence rates of 1.0% to < 5.0%

Cardiac disorders: hypertension

Gastrointestinal disorders: dyspepsia, flatulence

General disorders: abdominal pain, accidental injury, chills, fever, flu syndrome, neck pain, pelvic pain

Investigations: hyperglycemia, urine abnormality

Metabolism and nutrition disorders: peripheral edema, weight loss

Musculoskeletal, connective tissue and bone disorders: myalgia

Nervous system disorders: paresthesia, tremor, withdrawal syndrome

Psychiatric disorders: agitation, anxiety, apathy, confusion, depersonalization, depression, euphoria, nervousness

Respiratory, thoracic and mediastinal disorders: bronchitis, pharyngitis, rhinitis, sinusitis

Skin and subcutaneous tissue disorders: rash

Urogenital disorders: prostatic disorder, urinary tract infection

Vascular disorders: vasodilatation

Adverse reactions with incidence rates of 0.5% to < 1.0% at any dose and serious adverse reactions reported in at least two patients.

Cardiac disorders: EKG abnormal, hypotension, tachycardia

Gastrointestinal disorders: gastroenteritis

General disorders: neck rigidity, viral infection

Hematologic/Lymphatic disorders: anemia, ecchymoses

Metabolism and nutrition disorders: blood urea nitrogen increased, GGT increased, gout, SGPT increased

Musculoskeletal disorders: arthritis, arthrosis, joint disorder, leg cramps

Nervous system disorders: emotional lability, hyperkinesia, hypertonia, thinking abnormal, twitching, vertigo

Respiratory disorders: pneumonia

Skin and subcutaneous tissue disorders: hair disorder, skin disorder, urticaria

Special Senses: eye disorder, lacrimation disorder

Urogenital disorders: cystitis, dysuria, sexual function abnormality, urinary retention

Read the entire FDA prescribing information for ConZip (Tramadol Hydrochloride Extended-release Capsules)

Related Resources for ConZip

© ConZip Patient Information is supplied by Cerner Multum, Inc. and ConZip Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors